If it's not to late to enter your contest, I'll go with IMGN for the next year. I truly believe that IMGN's market cap ought to approach that of SGEN, which potentially brings it's price over that of SGEN as they have so many more shares outstanding. I believe a review of their pipelines and the potential of the drugs in each make them very comparable in terms of how they ought to be valued.
Rumors that SGEN would be bought out have tended to boost SGEN's share price over the years, and perhaps some day they'll be true. As for IMGN, I know they resisted such a move decades ago, but am unaware of any recent move on them, or whether their attitude about it has changed. In my memory, I believe that Roche has a substantial position in SGEN, I don't believe any of IMGN's partners have a similar interest. Part of the defense that both companies have to a hostile takeover is the number of partnerships they each have with a variety of major biotech's and pharma's. A takeover offer for either company could ignite a bidding war that truly would be a beautiful thing for investors.
I've been a shareholder to various degrees in IMGN practically from the day it came public. I still believe it's potential is tremendous, but certainly other technologies like CAR-T have tremendous potential as well. On a personal basis I received stem cells about 8 months ago in treatment of PH+ ALL at City of Hope. I know that if I should come out of remission, they would consider the use of T-cells technology that actually was developed there in the first place. Frankly it's amazing how many drugs in common usage today were first developed at City of Hope, one that's been very important to IMGN is Herceptin. I'm very much bothered by the way big Pharma operates, they make the big money while others, tiny biotechs and research institutions like City of Hope do the really exciting development of new drugs.
Gary |
